Lipid Disorders
From the Journals
‘Embarrassing’: High-intensity statin uptake in ASCVD patients ‘terrible’
A national study uncovered abysmal rates of usage for one of the most studied and inexpensive therapies available.
Conference Coverage
New research holds promise for fighting obesity, says expert
A growing understanding of adipose tissue as an endocrine organ responsible for weight control opens avenues for treatment, she says.
From the Journals
Traumatic brain injury linked to ‘striking’ risk for CVD, diabetes, brain disorders
Mild and moderate-to-severe TBI is linked to an increased risk for hypertension, stroke, diabetes, as well as neurological and psychiatric...
Feature
Tirzepatide succeeds in obesity in SURMOUNT-1, says Lilly
The once-weekly investigational twincretin drug is in phase 3 development for obesity and under regulatory review, with a decision expected soon...
From the Journals
Icosapent ethyl’s CV mortality benefit magnified in patients with prior MI
On top of statin therapy, icosapent ethyl provides mortality reductions in patients with prior MI.
From the Journals
Bariatric surgery cuts cardiovascular events, even in seniors
In persons with obesity, even those aged 65-75 years of age, bariatric surgery can reduce long-term cardiovascular events, such as heart failure,...
From the Journals
Fresh data confirm healthy plant foods link to lower diabetes risk
Metabolites contained in whole grains, fruits, and vegetables seem to be the key to reducing risk of developing type 2 diabetes in those who...
From the Journals
The best statins to lower non-HDL cholesterol in diabetes?
Rosuvastatin, simvastatin, and atorvastatin were most effective in reducing levels of non-HDL cholesterol in people with diabetes in a network...
Guidelines
AHA statement addresses CVD risk in NAFLD
The American Heart Association has issued a new scientific statement addressing cardiovascular risk in nonalcoholic fatty liver disease.
From the Journals
Erectile dysfunction drugs linked to ocular conditions
“Generally speaking, if [patients taking these agents] experience visual problems or changes in vision, then these drugs may be the culprits, and...
From the Journals
Novel tool could calculate CVD risk in T2DM
A blood pressure polygenic risk score using 1,000 genetic variants has shown the potential to calculate cardiovascular risk in people with...